Aug 2026· Therapeutic Innovation and Regulatory Science· 0 citations· 54 references
Medicine
TL;DR
This narrative review explores the evolving role of biomarkers across cardiovascular, renal, neurological, metabolic, metabolic, and respiratory diseases, focusing on their clinical and regulatory contexts of use-diagnostic, prognostic, predictive, surrogate, safety, and pharmacodynamic/response.
The biological rationale rooted in the genomic basis of cancer and the concept of oncogene addiction is outlined, and the enabling technologies - next-generation sequencing, comprehensive genomic profiling, large reference atlases, and liquid biopsy - are described that have made molecular characterization feasible in...
Mohd Faizan Siddiqui· International Research Journ...· 0 citations
No single biomarker is sufficient to guide management across all clinical scenarios, however, a multimodal strategy incorporating biomarkers, imaging, and clinical assessment is increasingly recommended and standardization and validation of these strategies remains needed.
Jea-Eun Kim, B. Lee, Audrey White et al.· Current Cardiology Reports· 0 citations
Modern medicine is being reshaped by advances in diagnostics, therapeutics, precision medicine, digital health, and artificial intelligence (AI). This multidisciplinary review examines how these developments influence patient care across internal medicine, cardiology, neurology, oncology, obstetrics and gynecology, ped...
R. Manikandan· Natural Resources for Human...· 0 citations
Background: Precision oncology aims to individualize cancer prevention, diagnostic stratifications, prognostication, and therapeutic regimens by synthesizing tumor biology with patient-specific clinical, demographic, and multi-omic characteristics. The exponential volume, velocity, and multi-scale complexity of contemp...
Goil Abhishek, Nrip Nripesh Kumar· Indian Journal of Computer S...· 0 citations
This narrative review examines the critical role of biomarkers in advancing personalized treatment strategies for GI cancers, highlighting biomarker-driven approaches across different GI cancer types and demonstrating how molecular profiling informs early detection, treatment selection, and monitoring of therapeutic re...
S. Mehrabadi· Anti-Cancer Agents in Medici...· 0 citations
Advances in next-generation sequencing, artificial intelligence, and additive manufacturing have driven pharmacogenomic drug optimization, biomarker-guided targeted therapies, and on-demand production of customized dosage forms, but future progress depends on expanding genomic diversity, building curated multi-omics re...
Janhavi Patil, Diya H. Aga, Sneha Yadav et al.· Fabad journal of pharmaceuti...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.